Winners named in NHS healthcare inequality contest
pharmaphorum
JANUARY 18, 2024
AI-powered patient risk assessment company C2-Ai and the Sickle Cell Society have won an NHS contest to find solutions that can tackle health inequality
society nhs 
Standardised uniforms for NHS trust pharmacists and pharmacy technicians revealed
Hospital Pharmacy Europe
OCTOBER 2, 2023
Standardised national uniforms for healthcare professionals in clinical roles at NHS trusts across England, including pharmacists and pharmacy technicians, have been revealed after a lengthy consultation and design process led by NHS Supply Chain. Together we are building a shared identity we can be proud of.’
Hospitals 
104
104 Hospitals 104
104 Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
RPS manifesto outlines key pharmacy priorities ahead of upcoming UK general election
Hospital Pharmacy Europe
JANUARY 10, 2024
The Royal Pharmaceutical Society (RPS) is calling on pharmacists across the UK to engage with their MPs and local prospective parliamentary candidates to help ensure pharmacy is part of health service debates ahead of the next general election.
Patient Care 105
105 
EU pharmacists joining NHS workforce to have automatic recognition for at least five more years
Hospital Pharmacy Europe
JULY 13, 2023
Pharmacists and other healthcare professionals from the EU can continue to join the NHS workforce for the next five years without taking additional tests, following a recent UK Government review. A version of this story was originally published by our sister publication Pulse.
Hospitals 96
96 Hospitals 96
96 
NHS workforce plan further delayed over cost concerns
Hospital Pharmacy Europe
MAY 31, 2023
The Government’s long-awaited NHS workforce plan appears to have been delayed as rumours circulate that it is too expensive. According to deputy chief executive of NHS Providers Saffron Cordery, the plan, which was expected for publication on 30 May, has been delayed further.
First treatment recommended for infants with Wolman Disease
European Pharmaceutical Review
NOVEMBER 27, 2023
NICE’s recommendation means that “babies born with Wolman Disease and their parents access to a new treatment option,” Bob Stevens, Group Chief Executive of the MPS Society commented. Kanuma replaces the deficient LAL enzyme and reduces the accumulation of fatty materials in cell lysosomes in the body.
Hospitals 95
95 
Crucial role of pharmacists in safe and effective healthcare celebrated on World Pharmacists Day
Hospital Pharmacy Europe
SEPTEMBER 25, 2023
Our profession inspires me every day’ Professor Claire Anderson, president of the Royal Pharmaceutical Society (RPS), described World Pharmacists Day as ‘a moment to reflect on our accomplishments as a profession and express gratitude for the remarkable efforts of pharmacy teams in promoting and preserving health.’
First pharmacists complete RPS e-portfolio pathway for advanced practice in England
Hospital Pharmacy Europe
OCTOBER 5, 2023
The first pilot cohort of pharmacists have completed the Royal Pharmaceutical Society (RPS) advanced e-portfolio pathway, which was launched in March 2023 to recognise and quality assure advanced pharmacist practice in England.
Hospitals 111
111 Hospitals 111
111 
First patients given lab-grown blood cell transfusion
European Pharmaceutical Review
NOVEMBER 7, 2022
Stem cells from blood donors were separated and grown to produce modified red blood cells at NHS Blood and Transplant ( NHSBT ) Advanced Therapies Unit in Bristol. This will help determine if the modified cells last longer than standard cells made in the body.
Hospitals 113
113 Hospitals 113
113 
Five new council members appointed by the GPhC for 2024 and 2025
Hospital Pharmacy Europe
FEBRUARY 15, 2024
The General Pharmaceutical Council (GPhC) has announced the appointment of five new members to its governing council, including the group chief pharmacist at Barts Health NHS Trust. Mr Williams is also associate non-executive director at both the North Bristol NHS Trust and the Southern Health NHS Foundation Trust.
Hospitals 52
52 Hospitals 52
52 
siRNA therapy shows long-term potential in lowering LDL-C
European Pharmaceutical Review
AUGUST 28, 2023
This is based on three-year follow up data from a Phase III trial, presented at the European Society of Cardiology (ESC) Congress 2023.
FDA 97
97 FDA 97
97 
Penicillin allergy labels can be safely removed for most patients, study suggests
Hospital Pharmacy Europe
MARCH 26, 2024
Within the NHS, there is no point-of-care test for penicillin allergy, and tests are onerous and time-consuming. And in October 2023, the Royal Pharmaceutical Society warned that millions could be missing out on the most effective antibiotic choice because they mistakenly believe they are allergic to penicillin.
Labelling 52
52 
NICE firms up NHS use of Vimizim for Morquio A syndrome
pharmaphorum
MARCH 21, 2022
Now – almost seven years later – it has upgraded the drug to routine NHS use. ” Its an endorsement of NICE’s approach of allowing access whilst collecting long term clinical and cost effectiveness data, the first time this was attempted by the NHS in England.
52 
Medicines shortages investigation to be launched by the RPS
Hospital Pharmacy Europe
MARCH 14, 2024
A new project to investigate the causes of medicines shortages and help reduce their impact on patients and pharmacy practice is to be launched by the Royal Pharmaceutical Society (RPS). Medicines are a key part of NHS care and their supply chain is a critical part of the UK’s infrastructure.
Hospitals 52
52 
Study finds 10% of medicines in England are overprescribed
pharmaphorum
SEPTEMBER 22, 2021
The government said it intends to appoint a new National Clinical Director for Prescribing, who will oversee a three-year programme based on research and training to try to improve prescribing practices in the NHS. — Royal Pharmaceutical Society (@rpharms) September 22, 2021.
Hospitals 100
100 Hospitals 100
100 
First treatment recommended for infants with Wolman Disease
European Pharmaceutical Review
NOVEMBER 27, 2023
NICE’s recommendation means that “babies born with Wolman Disease and their parents access to a new treatment option,” Bob Stevens, Group Chief Executive of the MPS Society commented. Kanuma replaces the deficient LAL enzyme and reduces the accumulation of fatty materials in cell lysosomes in the body.
Hospitals 59
59 
Government progress on pharmacy in England ‘requires improvement’
Hospital Pharmacy Europe
JULY 27, 2023
Paper prescribing commitment missed Once such ‘inadequate’ commitment by Government was to eliminate paper prescribing in hospitals and introduce digital or e-prescribing across the entire NHS by 2024. The report stated: ‘This commitment will not be achieved by 2024, with only 3% of Trusts having achieved the commitment so far.
Increasing momentum for climate and health championed by COP28 and pharmacy bodies
Hospital Pharmacy Europe
DECEMBER 19, 2023
Pharmacists‘ Defence Association (PDA) director Paul Day added: ‘Increasingly, pharmacists are considering the climate impact of their own practice alongside the wider impact of society on sustainability and the potential consequences for health.
Hospitals 52
52 Hospitals 52
52 
RPS seeks pharmacist feedback on ‘green guide‘ ahead of hospital pharmacy toolkit launch
Hospital Pharmacy Europe
NOVEMBER 2, 2023
The Royal Pharmaceutical Society (RPS) is seeking feedback from hospital pharmacists on its green guide to making professional pharmacy practice more environmentally sustainable. To support the documents, in spring 2024 the RPS will launch a Greener Pharmacy Toolkit, allowing pharmacies to self-accredit their sustainability status.
Hospitals 52
52 
Pegunigalsidase alfa receives NICE approval for Fabry disease
Hospital Pharmacy Europe
SEPTEMBER 7, 2023
It was found to be similarly clinically effective and as tolerable as the treatments for Fabry disease used currently in the NHS, and costs less. This approval makes it the first ERT treatment recommended for routine NHS use by NICE.
Hospitals 52
52 Hospitals 52
52 
Parliamentary probe finds racism evidence in NHS sickle cell care
pharmaphorum
NOVEMBER 15, 2021
Patients with sickle cell disease are facing racism in the NHS that is putting their lives a risk, claims a new report. . Cross-party MPs have urged health secretary Sajid Javid and the NHS to take urgent action to address the problem. The post Parliamentary probe finds racism evidence in NHS sickle cell care appeared first on.
Tackling health inequalities in children and young people
NICE
JUNE 15, 2023
At NICE, we define health inequalities as unfair and avoidable differences in health across the population and between different groups of society. There is an economic impact too, with estimates suggesting health inequalities cost the NHS an extra £4.8 billion a year, and society around £31 billion in lost productivity.
Hospitals 52
52 Hospitals 52
52 
Utrogestan accepted as HRT in Scotland
European Pharmaceutical Review
DECEMBER 12, 2022
The SMC approval of Utrogestan is limited within NHS Scotland. Dr Claire Phipps explained: “This decision from the Scottish Medicines Consortium (SMC) is a real milestone… [for] women in the management of their menopause symptoms…” . The SMC Executive’s approval is an important step towards greater patient equity across the UK.”.
105 
Novo Nordisk gets NICE okay for obesity drug Wegovy
pharmaphorum
FEBRUARY 8, 2022
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. billion to the NHS and £27 billion to wider society.
Labelling 105
105 Labelling 105
105 
Advice for pharmacy to reduce environmental impact of surgical care outlined in new report
Hospital Pharmacy Europe
NOVEMBER 28, 2023
Involving significant input and collaboration with individuals and organisations working across the surgical care pathway , the report is aimed at everyone involved in surgical care, including colleges, associations and societies, the NHS, suppliers, policy makers, clinicians, pharmacy teams and patients.
Calls for urgent action to tackle burnout across UK pharmacy sector
Hospital Pharmacy Europe
OCTOBER 9, 2023
The Workforce Wellbeing Roundtable report , published on 4 October by the Royal Pharmaceutical Society (RPS) and Pharmacist Support, provides an overview of the current wellbeing issues faced by pharmacy teams across all sectors of pharmacy in the UK.
Hospitals 52
52 Hospitals 52
52 
Utrogestan approved as HRT in Scotland
European Pharmaceutical Review
DECEMBER 12, 2022
The SMC approval of Utrogestan is limited within NHS Scotland. Dr Claire Phipps explained: “This decision from the Scottish Medicines Consortium (SMC) is a real milestone… [for] women in the management of their menopause symptoms…” . The SMC Executive’s approval is an important step towards greater patient equity across the UK.”.
97 
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
pharmaphorum
MAY 12, 2021
NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decides to drop its price.
83 
How can the pharma industry help build a greener NHS?
pharmaphorum
JUNE 21, 2021
NHS England has set its sights on becoming the world’s first net zero health system by 2045 – so what is industry doing to help achieve this goal, and what more needs to be done? . That is what the greener NHS programme is all about.”. We do not work in a bubble: we are part of society. Creating a healthier world.
ABPI chief exec on the UK industry’s learnings from COVID-19
pharmaphorum
DECEMBER 16, 2020
But Torbett says that right from the start of the pandemic there was a recognition of the challenges society and the NHS faced, and an “extraordinary” desire from the industry to support the national effort in every way it conceivably could. “We’ve That had a significant impact on companies.”. We’re very grateful for that.
Vaccines 120
120 Vaccines 120
120 
Consternation as NICE rejects Janssen MS drug Ponvory
pharmaphorum
OCTOBER 8, 2021
NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s not good news for patients with the disease waiting for new treatment options. The MS Society says that despite a growing list of approved therapies for MS, oral options are still limited in number.
52 
AI in action: Report highlights the real-world benefits of AI in healthcare
pharmaphorum
MAY 11, 2021
Aging populations, a growing number of people living with long-term conditions, and dwindling resources meant the NHS was already being asked to do more with less before COVID-19 hit. The NHS AI Lab, set up in 2019 in partnership with the Accelerated Access Collaborative, was designed to change that. Embracing AI potential.
Compounding 108
108 
UK patient group warns COVID could limit access to Novartis’ new eye drug
pharmaphorum
FEBRUARY 3, 2021
NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – but a patient group warned that access could be limited until the pandemic recedes because of disruption to ophthalmology clinics. When the coronavirus crisis is over we hope we will see the effects of this drug.
Labelling 98
98 
UK patients urged to self-care ahead of vaccine roll-out
pharmaphorum
DECEMBER 1, 2020
The survey of 2,200 adults and 100 GPs showed that 67% of family doctors urged patients to take greater responsibility for their own health and relieve pressure on the NHS as restrictions continue. million A&E admissions every year, costing the NHS over £2 billion. Minor conditions are responsible for 57 million GP visits and 3.7
Vaccines 63
63 Vaccines 63
63 
MHRA grants bluebird ‘innovation passport’ for sickle cell therapy
pharmaphorum
JUNE 30, 2021
bluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced in the UK earlier this year to speed up NHS access to promising new medicines. That was relaxed earlier this year and treatment is resuming.
FDA 98
98 FDA 98
98 
NICE rejects BMS’ Zeposia MS pill in provisional guidance
pharmaphorum
JANUARY 22, 2021
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance. In a statement, the MS Society said it was “frustrating” that NICE had decided not to recommend funding for Zeposia.
96 
GM herpes virus fights advanced cancers
European Pharmaceutical Review
SEPTEMBER 26, 2022
At the 2022 European Society for Medical Oncology Congress (ESMO) conference, promising results from a Phase I trial, suggesting that a novel genetically modified (GM) herpes virus eradicated or reduced advanced cancers, were presented.
Immunization 92
92 Immunization 92
92 
UK’s second go at a contact tracing app heads for pilot study
pharmaphorum
AUGUST 14, 2020
The new NHS Test and Trace app is intended to be used as an add-on to the controversial national and local contact-tracing service, and was due to start initial trials yesterday on the Isle of Wight and among a group of NHS volunteers. — NHS Test and Trace app (@NHSTestTraceapp) June 17, 2020.
114 
NICE backs ‘real-world’ wearable devices for Parkinson’s disease
pharmaphorum
SEPTEMBER 27, 2022
Five wearable devices that monitor patients with Parkinson’s disease as they go about their lives have been given a provisional recommendation from NICE, making them available via the NHS while additional data is collected. Main image source: Global Kinetics Corporation.
96 
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
pharmaphorum
AUGUST 11, 2020
In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Sahota sits on the ABPI board and leads one of the Association’s workstreams on engaging with the NHS on collaborations.
Packaging 110
110 
Pilot of non-antibiotic method to prevent surgical site infections begins at UK hospital
Hospital Pharmacy Europe
AUGUST 3, 2023
Dr Stuart Bond, consultant antimicrobial pharmacist and director of innovation at Mid Yorkshire Teaching NHS Trust, commented: ‘We are very pleased to be the first NHS trust in the UK to pilot this exciting, non-antibiotic method of preventing infections after surgery. Moreover, the technique does not harm human tissue.
Hospitals 52
52 Hospitals 52
52 
In conversation with consultant pharmacist in cardiology Dr Rani Khatib
Hospital Pharmacy Europe
APRIL 12, 2024
As well as a consultant pharmacist in cardiology and cardiovascular research at Leeds Teaching Hospitals NHS Trust, he is visiting associate professor at the Leeds Institute for Cardiometabolic Medicine at the University of Leeds.
Hospitals 83
83 
Vast majority of hospital pharmacists at risk of burnout, new RPS wellbeing survey shows
Hospital Pharmacy Europe
FEBRUARY 29, 2024
Almost nine in 10 hospital pharmacists are at high risk of burnout, according to the results of the fifth annual workforce and wellbeing survey from the Royal Pharmaceutical Society (RPS). She called for ‘collaborative efforts from governments, employers and the NHS to create more supportive and fulfilling work environments’.
Hospitals 52
52 
NICE approves semaglutide for weight loss
Hospital Pharmacy Europe
MARCH 9, 2023
.’ The release also cites data from a 2019 Health Survey for England, which estimated that 28% of adults in England were obese and a further 36% were overweight and that the government estimated that the current NHS costs of obesity in the UK were £6.1 billion and £27 billion to wider society.
Hospitals 98
98 Hospitals 98
98 
Let's personalize your content